NCT00017342CompletedPhase 2
Phase II Study Of Bryostatin 1 (NSC 339555) And High-Dose 1-B-D-Arabinofuranosylcytosine (HiDAC) In Patients With Refractory Leukemia
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Locations
- 6
Study Overview
Brief Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of combining bryostatin 1 with cytarabine in treating patients who have relapsed primary acute myelogenous leukemia.
Detailed Description
OBJECTIVES:
- Determine the response rate in patients with primary acute myelogenous leukemia in first relapse treated with bryostatin 1 and high-dose cytarabine.
- Determine the toxic effects of this regimen in these patients.
- Determine the relapse-free survival and overall survival of patients treated with this regimen.
OUTLINE: This is a multicenter study.
- Induction: Patients receive bryostatin 1 IV over 24 hours on days 1 and 11. Patients also receive high-dose cytarabine IV over 3 hours every 12 hours for 4 infusions on days 2-3 and days 9-10.
Patients who achieve a major response receive a second course of induction therapy.
Study Design
- Study Type
- Interventional
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Study Sites (6)
Loading locations...
Similar Trials
Completed
Phase 2
Combination Chemotherapy in Treating Patients With Unresectable Locally Advanced or Metastatic Stomach CancerGastric CancerEsophageal CancerNCT00006081M.D. Anderson Cancer Center37
Completed
Phase 2
Bryostatin-1 Plus Cisplatin in Treating Patients With Recurrent or Advanced Cancer of the CervixCervical CancerNCT00005965Icahn School of Medicine at Mount Sinai
Completed
Phase 1
Bryostatin 1 and High Dose Cytarabine in Treating Patients With Refractory or Relapsed Leukemia or LymphomaLymphomaLeukemiaNCT00003079Virginia Commonwealth University30
Completed
Phase 2
Bryostatin 1 in Treating Patients With Recurrent or Refractory Hodgkin's DiseaseLymphomaNCT00003936Barbara Ann Karmanos Cancer Institute
Completed
Phase 2
Bryostatin 1 in Treating Patients With Myelodysplastic SyndromeMyelodysplastic SyndromesLeukemiaNCT00003171Barbara Ann Karmanos Cancer Institute